In pair of decisions, judges curtail using generics’ sham-litigation claims against them later


The following article first appeared on Dec. 15 on MLex. For more information on MLex, including getting access to its exclusive content, please contact¬ sales@mlex.com. ¬ Generic drugmakers cannot be found automatically liable for antitrust violations for settling patent litigation that involves a patent they think may have